2
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Approved for marketing
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
54
Observational
8
Expanded_access
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia
1
Interventions
3-Iodobenzylguanidine
9
Amifampridine
6
nilotinib
5
Magnetic Resonance Spectroscopy
5
Cyclophosphamide
5
trametinib
4
pembrolizumab
4
gallium 68 PSMA-11
4
fludarabine
4
elotuzumab
4
dabrafenib
4
Nivolumab
4
Bortezomib
4
Afatinib
4
venetoclax
3
regorafenib
3
midostaurin
3
fludarabine phosphate
3
TIC10 compound
3
Sunitinib
3
Prednisone
3
Lenalidomide
3
Ipilimumab
3
Everolimus
3
Dexamethasone
3
Crizotinib
3
Capecitabine
3
Axitinib
3
Alpelisib
3
Abiraterone Acetate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Expanded_access
×
ponatinib
×
Clear all
NCT01592136
2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing
NCT01549548
2013-03-15
Compassionate Use Ponatinib
OHSU Knight Cancer Institute
No longer available